Thomas Powles, MD, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.
Thomas Powles, MD, Barts Cancer Institute, shares his advice for community oncologists treating patients with bladder cancer in the frontline setting. According to Powles, this is a setting where there is a lot of uncertainty that can make decision making difficult.
Powles advises clinicians treat patients who are biomarker-positive with immunotherapy, particularly those who will benefit from chemotherapy if the immunotherapy does not work. This also includes patients who have relatively low aggressive disease or rapidly progressive liver metastases.
For patients with slow progressive bladder cancer, clinical trials are looking for more attractive approaches than chemotherapy for these patients. While data are still not available from randomized trials, it is best to air on the safe side with chemotherapy treatment.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More